Teva Loses Pravachol Exclusivity Period; Multiple Generics To Launch In 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells Teva that the 180-day exclusivity period for three pravastatin doses expired in February. As a result, as many as six companies – including Teva – could be in a position to launch generic Pravachol when Bristol’s composition of matter patent expires in April 2006. Teva plans to sue FDA to reinstate its first-to-file exclusivity period.
You may also be interested in...
Teva’s Generic Pravachol Will Be Approved – With Exclusivity, FDA Decrees
FDA has determined that a court dismissal does not constitute a decision under the “court decision trigger” provision, although the agency’s stance must be affirmed by the D.C. district court.
Teva’s Generic Pravachol Will Be Approved – With Exclusivity, FDA Decrees
FDA has determined that a court dismissal does not constitute a decision under the “court decision trigger” provision, although the agency’s stance must be affirmed by the D.C. district court.
Pravachol Exclusivity Case Remanded To FDA By Appeals Court
FDA needs to develop policy to determine whether a voluntary patent case dismissal triggers exclusivity, the court said.